Nanocarrier-Mediated Nucleic Acid Therapy in Non-Small Cell Lung Cancer: Converging Delivery Barriers, Resistance Reversal, and Clinical Translation.
Future nanocarrier-based gene therapy for NSCLC should move beyond material innovation toward barrier-informed, resistance-matched, biomarker-guided, and clinically scalable precision nanomedicine.